Abstract
Experts from the European Society of Hypertension prepared this position paper in order to summarize current evidence, unmet needs and practical recommendations on the application of percutaneous transluminal ablation of renal nerves [renal denervation (RDN)] as a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RND. Clinical studies have documented that catheter-based RDN decreases both efferent sympathetic and afferent sensory nerve traffic leading to clinically meaningful systolic and diastolic blood pressure (BP) reductions in patients with resistant hypertension. This position statement intends to facilitate a better understanding of the effectiveness, safety, limitations and issues still to be addressed with RDN.
| Original language | English |
|---|---|
| Pages (from-to) | 837-841 |
| Number of pages | 5 |
| Journal | Journal of Hypertension |
| Volume | 30 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2012 |
Fingerprint
Keywords
- European Society of Hypertension
- interventional therapy
- resistant hypertension
ASJC Scopus subject areas
- Internal Medicine
- Physiology
- Cardiology and Cardiovascular Medicine
Cite this
ESH Position Paper : Renal denervation-an interventional therapy of resistant hypertension. / Schmieder, Roland E.; Redon, Josep; Grassi, Guido; Kjeldsen, Sverre E.; Mancia, Giuseppe; Narkiewicz, Krzysztof; Parati, Gianfranco; Ruilope, Luis; Van De Borne, Philippe; Tsioufis, Costas.
In: Journal of Hypertension, Vol. 30, No. 5, 05.2012, p. 837-841.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - ESH Position Paper
T2 - Renal denervation-an interventional therapy of resistant hypertension
AU - Schmieder, Roland E.
AU - Redon, Josep
AU - Grassi, Guido
AU - Kjeldsen, Sverre E.
AU - Mancia, Giuseppe
AU - Narkiewicz, Krzysztof
AU - Parati, Gianfranco
AU - Ruilope, Luis
AU - Van De Borne, Philippe
AU - Tsioufis, Costas
PY - 2012/5
Y1 - 2012/5
N2 - Experts from the European Society of Hypertension prepared this position paper in order to summarize current evidence, unmet needs and practical recommendations on the application of percutaneous transluminal ablation of renal nerves [renal denervation (RDN)] as a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RND. Clinical studies have documented that catheter-based RDN decreases both efferent sympathetic and afferent sensory nerve traffic leading to clinically meaningful systolic and diastolic blood pressure (BP) reductions in patients with resistant hypertension. This position statement intends to facilitate a better understanding of the effectiveness, safety, limitations and issues still to be addressed with RDN.
AB - Experts from the European Society of Hypertension prepared this position paper in order to summarize current evidence, unmet needs and practical recommendations on the application of percutaneous transluminal ablation of renal nerves [renal denervation (RDN)] as a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RND. Clinical studies have documented that catheter-based RDN decreases both efferent sympathetic and afferent sensory nerve traffic leading to clinically meaningful systolic and diastolic blood pressure (BP) reductions in patients with resistant hypertension. This position statement intends to facilitate a better understanding of the effectiveness, safety, limitations and issues still to be addressed with RDN.
KW - European Society of Hypertension
KW - interventional therapy
KW - resistant hypertension
UR - http://www.scopus.com/inward/record.url?scp=84859898722&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859898722&partnerID=8YFLogxK
U2 - 10.1097/HJH.0b013e328352ce78
DO - 10.1097/HJH.0b013e328352ce78
M3 - Article
C2 - 22469838
AN - SCOPUS:84859898722
VL - 30
SP - 837
EP - 841
JO - Journal of Hypertension
JF - Journal of Hypertension
SN - 0263-6352
IS - 5
ER -